patient recruitment News
-
Longenesis joins Salto Growth Camp: EMERGEncy, a 100-hour online accelerator to address the COVID-19 crisis
Throughout this week Longenesis will be intensively working with mentors and investors (including Skype and Bolt co-Founders) to create and validate a concept for post-COVID-19 data utilization for research, faster drug development and patient recruitment. We believe that the tools developed by Longenesis have found a perfect fit in solving challenges in data and patient cohort identification ...
By Longenesis
-
Ascelia Pharma suspends clinical activities in Russia
Ascelia Pharma AB (publ) (ticker: ACE) today announced that due to the Russian invasion of Ukraine, all clinical activities in Russia in the ongoing Phase 3 study SPARKLE are being suspended. As a consequence, the expected recruitment completion for the SPARKLE study is extended to 2022 (previously H1 2022). The consequences of Russia’s invasion of Ukraine are both grave and ...
-
Ondine completes enrollment for US Phase II nasal photodisinfection trial
Ondine Biomedical Inc. (LON: OBI), has recruited the final patient to its nasal photodisinfection exploratory Phase 2 trial. The trial is evaluating how effectively Ondine’s nasal photodisinfection technology eradicates pathogens – specifically Staphylococcus aureus – in the nose. The single-center, BENEFIT-aPDT open-label study is being carried out at HCA Healthcare’s ...
-
Camurus announces dosing initiated in Phase 3 study of CAM2029 in patients with neuroendocrine tumors
Camurus (NASDAQ STO: CAMX) today announces that dosing has been initiated in the company’s randomized, active-controlled Phase 3 study, SORENTO, which aims to evaluate the efficacy and safety of octreotide subcutaneous depot (CAM2029) in the treatment of patients with neuroendocrine tumors localized in the gastrointestinal tract or pancreas (GEP-NET). “There is a high unmet medical ...
By Camurus AB
-
Clinical study authorised in Sweden for the investigation of CDNF and Renishaw drug delivery system in Parkinson`s patients
The Medicines Agency of Sweden, MPA, has authorised Herantis Pharma Plc and Renishaw plc's randomised, placebo-controlled Phase 1-2 clinical study, for the investigation of Cerebral Dopamine Neurotrophic Factor (CDNF) and Renishaw's chronic drug delivery system, in Parkinson's patients. The first study site to start patient recruitment will be the Karolinska University Hospital in Stockholm, ...
By Renishaw plc
-
Transgene confirms the potential of its two innovative platforms and expects significant clinical results in 2022
TG4050 (myvac): First positive results from the two Phase I trials. Additional data to be presented at AACR 2022 in April. TG4001: First patient enrolled in Phase II study in June 2021. Active patient recruitment in Europe and trial initiation in the US. Interim analysis expected in Q4 2022. BT-001 (Invir.IO™): IND approval for Phase I/IIa trial in the US, ongoing enrollment in Europe. ...
By Transgene
-
Lipella Pharmaceuticals Initiates its Phase-2a Clinical Trial of LP-10 for Hemorrhagic Cystitis
A multi-site, prospective, open-label, dose-escalation clinical trial assessing the safety and efficacy of LP-10 (liposomal tacrolimus) is now open for recruitment at several sites. PITTSBURGH, October 15, 2020 (BUSINESS WIRE) – Lipella Pharmaceuticals Inc., a clinical-stage pharmaceutical company focused on improving cancer survivorship, today announced it has begun recruiting patients in ...
-
Showcase
Are the patients able to perform the home spirometry with AioCare?
The Journal of Asthma published the results of a study that assessed asthma patients and their ability to perform high-quality daily spirometry with the AioCare system. The study has shown that home spirometry is safe without supervision and feasible for asthma patients. Abstract: Background: Self-management is an appealing strategy for the prevention of asthma exacerbations. This study aimed ...
By AioCare
-
ITM Receives FDA Fast Track Designation for Radionuclide Therapy Candidate ITM-11 (n.c.a. 177Lu-edotreotide) in Neuroendocrine Tumors (GEP-NETs)
ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that the U.S. Food and Drug Administration (FDA) has granted the company Fast Track designation for ITM-11 (n.c.a. 177Lu-edotreotide), an investigational radiopharmaceutical for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). ITM-11 is being evaluated as a Targeted ...
-
AioCare supports new medicine’s clinical trial to bring even more value for asthma therapy.
The AioCare system is used as a home self-monitoring tool in a prospective, observational cohort study of a drug for severe eosinophilic asthma, produced by one of the world’s pharmaceutical concerns. Fifty adult patients diagnosed with severe eosinophilic asthma (defined by blood eosinophilia ≥300 cells / μl and at least three asthma exacerbations in the previous year) will be ...
By AioCare
-
Bone Therapeutics to host Annual General Meeting and Extraordinary General Meeting on 8 June 2022
BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the cell therapy company addressing unmet medical needs in orthopedics, invites its shareholders and the holders of registered subscription rights and registered convertible bonds of the Company to the Annual General Meeting to be held on Wednesday 8 June 2022 as from 4:00 pm CEST, at Rue Granbonpré 11, Building H, 1435 ...
-
Transparency notification received from Nyenburgh Holding NV
BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the cell therapy company addressing unmet medical needs in orthopedics and other diseases, today announces that it has received a transparency notification dated 16 March 2022 indicating that the shareholdings held by Nyenburgh Holding NV have crossed below the minimum threshold of 5%. The notification dated 16 March 2022 contains the ...
-
CoNextions Inc. Announces Patient Enrollment in Clinical Trial for CoNextions TR System in South Africa
CoNextions Inc. (www.conextionsmed.com) announced today that its has enrolled its first two patients in a multicenter, blinded, randomized clinical trial comparing the CoNextions TR System to standard of care suture repair for repair of Zone 2 tendon lacerations. The first two patients were enrolled at Groote Schuur Hospital in Cape Town, South Africa. Five fellowship trained hand surgeons will ...
-
Promising treatment against COVID-19 and its variants: Quebec biotech, Immune Biosolutions begins Phase I clinical trial stages for its inhaled immunotherapy treatment
Immune Biosolutions is pleased to announce the start of Phase I clinical trial for its immunotherapy (IBIO123) treatment, whose antibodies have the potential to neutralize and eliminate COVID-19 and its variants. The treatment has the ability of being administered by inhalation and acts in a highly targeted manner through the lungs to fight the infection at its source. This treatments aims to be ...
-
endpoint and THREAD Simplify DCT Operations for Key Stakeholders to Reduce Study Timelines
endpoint Clinical, the leader in global interactive response technology (IRT®) for clinical trials, and THREAD, a leading technology and service provider enabling decentralized clinical trials (DCT), have announced their partnership to offer sponsors and sites a solution that simplifies DCT operations and reduces research study timelines. “Adoption of DCT technologies that are capable ...
-
Aurealis Therapeutics Diabetic Foot Ulcer Dose Escalation Patient Trial Low Therapeutic Dose Cohort Completed Successfully, Advances to Medium Therapeutic Dose Group
Aurealis Therapeutics, a biopharmaceutical company developing its groundbreaking four-in-one technology -based product AUP-16, announced today that it has successfully completed the low therapeutic dose cohort in the diabetic foot ulcer (DFU) patient trial and has already enrolled and dosed the first patients in the medium therapeutic dose cohort. The primary endpoint of this dose escalation ...
-
Bone Therapeutics signs definitive subscription agreement for a maximum of EUR 5M convertible bonds facility with ABO
BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the cell therapy company addressing unmet medical needs in orthopedics, today announces that it has signed the definitive subscription agreement for a maximum EUR 5 million convertible bonds (CBs) facility arranged by ABO Securities, through its affiliated entity Global Tech Opportunities 15. The proceeds of the financing will contribute to ...
-
Gesynta Pharma completes patient enrollment in its Phase II study in systemic sclerosis
Gesynta Pharma AB today announces that all patients have been recruited for the company's clinical Phase II study with the drug candidate GS-248, which is being evaluated as a treatment for the rare disorder systemic sclerosis.The study is intended to demonstrate proof-of-concept and to evaluate the safety profile of GS-248. Top-line data is expected in the fall of 2022. Systemic ...
-
Synairgen provides update on ACTIV-2 Trial
Synairgen plc (LSE: SNG), the respiratory company developing SNG001, a formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, today announces that the US National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) has halted all patient recruitment in its Phase 2/3 COVID-19 trial (Protocol ACTIV-2/A5401; ...
-
Immatics Announces Second Quarter 2021 Financial Results and Provides Business Update
Immatics N.V. (NASDAQ: IMTX; “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting cancer immunotherapies, today reported its financial results for the quarter ended June 30, 2021 and provided a business update on its progress over the reporting period. “An important development during the second quarter of 2021 ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you